TWI736243B - 二胺基嘧啶類化合物治療咳嗽的方法 - Google Patents

二胺基嘧啶類化合物治療咳嗽的方法 Download PDF

Info

Publication number
TWI736243B
TWI736243B TW109114696A TW109114696A TWI736243B TW I736243 B TWI736243 B TW I736243B TW 109114696 A TW109114696 A TW 109114696A TW 109114696 A TW109114696 A TW 109114696A TW I736243 B TWI736243 B TW I736243B
Authority
TW
Taiwan
Prior art keywords
days
compound
group
cough
alkyl
Prior art date
Application number
TW109114696A
Other languages
English (en)
Chinese (zh)
Other versions
TW202106302A (zh
Inventor
趙焰平
王紅軍
黃淮
姜媛媛
梁會寧
安然
蘭洲
王瑾
周麗瑩
劉亞男
Original Assignee
大陸商北京泰德製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京泰德製藥股份有限公司 filed Critical 大陸商北京泰德製藥股份有限公司
Publication of TW202106302A publication Critical patent/TW202106302A/zh
Application granted granted Critical
Publication of TWI736243B publication Critical patent/TWI736243B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109114696A 2019-04-30 2020-04-30 二胺基嘧啶類化合物治療咳嗽的方法 TWI736243B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2019/085180 2019-04-30
CN2019085180 2019-04-30

Publications (2)

Publication Number Publication Date
TW202106302A TW202106302A (zh) 2021-02-16
TWI736243B true TWI736243B (zh) 2021-08-11

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109114696A TWI736243B (zh) 2019-04-30 2020-04-30 二胺基嘧啶類化合物治療咳嗽的方法

Country Status (12)

Country Link
US (1) US20220211703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3960179B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665529B2 (cg-RX-API-DMAC7.html)
KR (1) KR102935436B1 (cg-RX-API-DMAC7.html)
CN (1) CN114007619B (cg-RX-API-DMAC7.html)
AU (1) AU2020265327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021600A2 (cg-RX-API-DMAC7.html)
ES (1) ES3067370T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021013338A (cg-RX-API-DMAC7.html)
SG (1) SG11202111877TA (cg-RX-API-DMAC7.html)
TW (1) TWI736243B (cg-RX-API-DMAC7.html)
WO (1) WO2020221274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
DK2343281T3 (en) 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途

Also Published As

Publication number Publication date
ES3067370T3 (en) 2026-05-21
JP7665529B2 (ja) 2025-04-21
JP2022530890A (ja) 2022-07-04
KR102935436B1 (ko) 2026-03-05
SG11202111877TA (en) 2021-11-29
MX2021013338A (es) 2022-01-24
BR112021021600A2 (pt) 2022-01-04
EP3960179A1 (en) 2022-03-02
KR20220007620A (ko) 2022-01-18
US20220211703A1 (en) 2022-07-07
AU2020265327A1 (en) 2021-12-16
CN114007619B (zh) 2024-08-06
EP3960179B1 (en) 2026-03-18
CN114007619A (zh) 2022-02-01
TW202106302A (zh) 2021-02-16
EP3960179A4 (en) 2023-01-25
CA3138780A1 (en) 2020-11-05
AU2020265327B2 (en) 2025-09-11
WO2020221274A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
TWI804743B (zh) 治療特發性肺纖維化的方法
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
TWI737285B (zh) 二胺基嘧啶類化合物治療子宮內膜異位相關的疼痛的方法
CN114007619B (zh) 二氨基嘧啶类化合物治疗咳嗽的方法
TWI868660B (zh) 治療造血幹細胞移植後的移植物抗宿主病的方法
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
EP4591863A1 (en) Method for treating pneumoconiosis
HK40063168B (en) Method for treating cough by using diaminopyrimidine compound
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40062124B (en) Method for treating cough by using diaminopyrimidine compound
HK40121343A (en) Method for treating idiopathic pulmonary fibrosis
HK40054971B (en) Method for treating fatty liver disease and/or steatohepatitis
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40063619B (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis